Bloomberg -- Astellas Pharma Inc. needs to increase its $3.5 billion hostile takeover bid for OSI Pharmaceuticals Inc. by 15 percent, said OrbiMed Advisors LLC, OSI’s fifth-biggest shareholder.
Bloomberg -- Astellas Pharma Inc. needs to increase its $3.5 billion hostile takeover bid for OSI Pharmaceuticals Inc. by 15 percent, said OrbiMed Advisors LLC, OSI’s fifth-biggest shareholder.
